2-methyl-2,3-dihydro-benzo[b]thiophene | 6165-55-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-methyl-2,3-dihydro-benzo[b]thiophene
• 英文别名: 2-Methyl-2,3-dihydro-benzo[b]thiophen；Benzo[b]thiophene, dihydromethyl-；2-methyl-2,3-dihydro-1-benzothiophene
• CAS: 6165-55-5
• 化学式: C₉H₁₀S
• 分子量: 150.244
• InChiKey: ZEAQOIXHQBWPOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-2,3-dihydro-benzo[b]thiophene 生成 (1R,2R)-2-methyl-2,3-dihydro-1-benzothiophene 1-oxide
  参考文献：
  名称：

  FUJIMORI, KEN;MATSUURA, TAKAHARU;MIKAMI, AKIHIRO;WATANABE, YOSHIHITO;OAE,+, J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N, C. 1435-1440

  摘要：

  DOI：
• 作为产物：
  描述：

  2-methyl-4H-benzo[a][1,3]oxathiine 在 磷酸 、 lithium 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.0h， 生成 2-methyl-2,3-dihydro-benzo[b]thiophene
  参考文献：
  名称：

  2-羟基和2-巯基苄醇的新同系物

  摘要：

  苯并-1,3-二恶烷或苯并-1,3-氧杂蒽1 [由2-羟基或2-巯基苄基醇（分别为3或4）和羰基化合物容易制得]与过量的锂和α在室温或-78°C下，DTBB在THF中的催化量（4.5摩尔％）导致水解后生成相应的均苄醇2。在酸性（85％H 3 PO 4）或中性（Ph 3 P / DIAD）条件下将化合物2环化，可得到预期的杂环5。

  DOI：

  10.1016/s0040-4020(97)10161-2

文献信息

• Investigating the microwave-accelerated Claisen rearrangement of allyl aryl ethers: Scope of the catalysts, solvents, temperatures, and substrates
  作者：Zi Hui、Songwei Jiang、Xiang Qi、Xiang-Yang Ye、Tian Xie

  DOI：10.1016/j.tetlet.2020.151995

  日期：2020.6

  The microwave-accelerated Claisen rearrangement of allyl aryl ethers was investigated, in order to gain insight into the scope of the catalysts, solvents, temperatures, and substrates. Among the catalysts examined, phosphomolybdic acid (PMA) was found to greatly accelerate the reaction in NMP, at temperatures ranging from 220 to 300 °C. This method was found to be useful for preparing several intermediates

  对微波加速烯丙基芳基醚的克莱森重排进行了研究，以便深入了解催化剂，溶剂，温度和底物的范围。在所考察的催化剂中，发现磷钼酸（PMA）在220至300°C的温度下可大大促进NMP中的反应。发现该方法对于使用贵金属催化剂例如Au（I），Ag（I）和Pt（II）制备先前在文献中报道的几种中间体是有用的。另外，在芳基部分带有溴和硝基的底物需要仔细调整反应条件，以避免复杂的产物分布。
• Derivatives of 5-Thioxylopyranose and Use of Same for Treatment
  申请人：Barberousse Veronique

  公开号：US20090182013A1

  公开（公告）日：2009-07-16

  The invention relates to new compounds of 5-thioxilose, preferably derivatives of the 5-thioxilopyranose type, and to a method for preparing the same and their use as the active ingredient of drugs mainly intended for treating or inhibiting thrombosis or heart failure or thromboembolic diseases.

  该发明涉及5-硫代木糖的新化合物，优选为5-硫代木糖吡喃糖类的衍生物，以及一种制备这些化合物的方法和它们作为药物活性成分的用途，主要用于治疗或抑制血栓形成、心力衰竭或血栓栓塞性疾病。
• The mechanistic mode of oxidation of substituted n,n-dimethylanilines, thioanisoles, and methyl phenyl sulfoxides by 5-ethyl-4a-hydroperoxy-3-methyl-lumiflavin (4a-FlEt-OOH)
  作者：Shigeru Oae、Kaoru Asada、Toshiaki Yoshimura

  DOI：10.1016/s0040-4039(00)81631-7

  日期：1983.1

  In the oxidation of the title compounds, 5-ethyl-4a-hydroperoxy-3-methyl-lumiflavin (4a-FlEt-OOH), was found to be an electrophilic oxidant similar to m-chloroperoxybenzoic acid. However, the stereoselectivity of the oxidation of cyclic sulfides to the corresponding sulfoxides by 4a-FlEt-OOH was less pronounced than that of the oxygenation with flavin-containing monooxygenase.

  在标题化合物的氧化中，发现5-乙基-4a-氢过氧-3-甲基-荧光黄素（4a-FlEt-OOH）是类似于间氯过氧苯甲酸的亲电子氧化剂。然而，通过4a-FlEt-OOH将环状硫化物氧化成相应的亚砜的立体选择性不如用含黄素的单加氧酶氧化的立体选择性强。
• Heterocyclic amino-alcohol derivatives
  申请人：Continental Pharma

  公开号：US04638070A1

  公开（公告）日：1987-01-20

  This invention relates to heterocyclic amino-alcohol derivatives of the formula ##STR1## These compounds are useful as antihypertensives.

  这项发明涉及公式为##STR1##的杂环氨基醇衍生物。这些化合物可用作降压药。
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。